Full Press Release Details
Oncolytics Biotech Inc. to Present at BioFianance
CALGARY, Alberta, --- April 27,
2009 - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc.
(TSX: ONC, NASDAQ: ONCY), is scheduled to present a corporate overview of the
Company at BioFinance 2009 on Wednesday, April 29 at 9:00 a.m.
(ET). The conference will be held at the Toronto Marriott
Eaton Centre from April 28-30, 2009.
2009 is the leading investor conference in Canada for the life sciences
industry. This three-day event brings together key industry players interested
in investment opportunities and issues affecting companies in the life sciences
Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company
focused on the development of oncolytic viruses as potential cancer
therapeutics. Oncolytics' clinical program includes a variety of
Phase I/II and Phase II human trials using REOLYSIN , its proprietary
formulation of the human reovirus, alone and in combination with radiation or
chemotherapy. For further information about Oncolytics, please visit
presentation time is subject to change. This release and the presentation
related thereto contain forward-looking statements which involve known and
unknown risks, delays, uncertainties and other factors not under the Company's
control and which may cause actual results, performance or achievements of the
Company to be materially different from the results, performance or expectations
implied by these forward-looking statements. Such risks and uncertainties
include, among others, the efficacy of REOLYSIN as a cancer treatment, the
success and timely completion of clinical studies and trials, uncertainties
related to the research and development of pharmaceuticals, uncertainties
related to the regulatory process and general changes to the economic
environment. Investors should consult the Company's quarterly and annual filings
with the Canadian and U.S. securities commissions for additional information on
risks and uncertainties relating to the forward-looking statements. Investors
are cautioned against placing undue reliance on forward-looking statements. The
Company does not undertake to update these forward-looking statements, except as
required by applicable laws.
FURTHER INFORMATION PLEASE CONTACT: